Your eligible patients pay no more than $15.

Coupon subject to eligibility restrictions and limitations described below.*

How many coupons would you like to print?

Help your patients actively participate in their cold sore treatment with prescription Denavir®. And put power at their fingertips.

Did you know that prescription Denavir® (penciclovir cream, 1%) has the same trusted mechanism of action as oral antivirals? Denavir targets the HSV-1 virus to inhibit viral DNA synthesis and replication.† 4,5

And as a cream, it has the benefit of enabling your patients to be actively involved in their treatment.

Denavir delivers:

  • Efficacy at your patients’ fingertips. Patients apply Denavir directly to the cold sore.4
  • Reduction in lesion duration. It also reduces the duration of pain associated with the lesion.4
  • Topical relief from discomfort, drying and cracking.2,4 Denavir is not systemically absorbed.‡ And it has no known drug interactions.4
  • A broad window of treatment. Unlike some other prescription and over-the-counter cold sore medications, Denavir can be initiated at the prodrome stage or when lesions appear.4
  • A well-tolerated treatment. In clinical trials, the most frequently reported adverse events were with Denavir and placebo in pivotal trials, respectively, were headache (5.3% vs. 5.8%) and application site reaction (1.3% vs. 1.8%).4
  • Convenience. Denavir is now available in a 5-gram tube, which can be used to treat multiple outbreaks — patients can be ready to treat as soon as the earliest symptoms occur.

† In in vitro studies.
‡ The systemic absorption of penciclovir following topical administration has not been evaluated in patients <18 years of age.


Expand Safety Information

Denavir® (penciclovir cream, 1%) is indicated for the treatment of recurrent herpes labialis
(cold sores) in adults and children 12 years of age and older.

Important Safety Information

Denavir should only be used on herpes labialis on the lips or face. Application to mucous membranes is not recommended. Denavir should not be used in patients with known hypersensitivity to the product or any of its ingredients.

There are no adequate and well-controlled Denavir studies in pregnant women; therefore, Denavir should be used during pregnancy only if clearly needed. There is no information on whether Denavir is excreted in human milk after topical administration; a decision whether to discontinue Denavir should take into account the importance of the drug to the mother. The effect of Denavir has not been established in immunocompromised patients. Denavir does not cure cold sores.

In clinical studies, the most common adverse reaction with Denavir was headache, which occurred in 5.3% of patients who received Denavir and 5.8% of patients who received placebo. Other adverse reactions with Denavir occurred in less than 2% of patients and included application site reaction, decreased sensitivity to touch/local anesthesia, taste perversion, and rash.

Other reported adverse reactions have included swelling of the mouth or throat, pain, alterations in sense of smell, abnormal touch sensation, itching, skin discoloration, and hives.

Denavir is available by prescription only. Please see the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.